<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00828672</url>
  </required_header>
  <id_info>
    <org_study_id>s51104 - ML5194</org_study_id>
    <secondary_id>2007-007177-23</secondary_id>
    <secondary_id>MO19051</secondary_id>
    <nct_id>NCT00828672</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer</brief_title>
  <acronym>AXEBEAM</acronym>
  <official_title>A Randomized Phase II Study of Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin in the Preoperative Treatment of Locally Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II clinical trial, open-label, randomized, two arms, multicentre (possibly
      multinational). Academic, investigator initiated.

      To assess the activity of bevacizumab (AvastinTM) in combination with capecitabine (XelodaTM)
      and radiation therapy with or without oxaliplatin (EloxatinTM) in the pre-operative treatment
      of locally advanced rectal cancer, followed by TME (total mesorectal excision).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See Synopsis
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2009</start_date>
  <completion_date type="Actual">March 2019</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Response at Surgery. Overview of Complete Pathologic Responses, Good and Little Tumour Regression Rates at Surgery.</measure>
    <time_frame>4 months</time_frame>
    <description>Dworak tumour regression grades (TRG) were used to assess pathologic response: TRG0=no regression. TRG1=dominant tumor mass with obvious fibrosis and/or vasculopathy; TRG2=dominant fibrotic changes with few tumour cells or groups; TRG3=very few (difficult to find microscopically) tumour cells in fibrotic tissue with or without mucus substance. TRG4=no intact viable tumour cells, only fibrotic mass or presence of mucin lakes without associated malignant cells (total tumour regression). Pathologic assessments of tumour response post chemoradiotherapy as provided by investigators (read by local pathologists on operative specimens) were reviewed centrally for all pts for whom surgical materials were available (centrally reviewed set). The diagnosis of independent central reviewers primed. Pathologic complete response rates (TRG4) are reported (%). Good (TRG3 and TRG4 together) and little (TRG 0,1 and 2) tumour regression rates are summarized. For these 2 last rows, % add to 100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Histopathologic R0 and Negative CRM Resection</measure>
    <time_frame>4 months</time_frame>
    <description>Histopathologic R0 resection rate was defined as margins histologically negative for tumour involvement after resection. The circumferential resection margin (CRM) is considered to be involved if microscopic tumour is present &lt;1mm from or at the inked circumferential or radial resection margin. Data on quality of mesorectal excision were expected but not collected consistently.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Pathologic Complete Response at Surgery. Number of Participants With Good or Little Pathological Tumour Regression at Surgery.</measure>
    <time_frame>4 months</time_frame>
    <description>Dworak tumour regression grades (TRG) were used to assess pathologic response: TRG0=no regression. TRG1=dominant tumor mass with obvious fibrosis and/or vasculopathy; TRG2=dominant fibrotic changes with few tumour cells or groups; TRG3=very few (difficult to find microscopically) tumour cells in fibrotic tissue with or without mucus substance. TRG4=no intact viable tumour cells, only fibrotic mass or presence of mucin lakes without associated malignant cells (total tumour regression). Pathologic assessments of tumour response post chemoradiotherapy as provided by investigators (read by local pathologists on operative specimens) were reviewed centrally for all pts for whom surgical materials were available (centrally reviewed set). The diagnosis of independent central reviewers primed. Pathologic complete response rates (TRG4) are reported (%). Good (TRG3 and TRG4 together) and little (TRG 0,1 and 2) tumour regression rates are summarized. For these 2 last rows, % add to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response Rate</measure>
    <time_frame>3 months</time_frame>
    <description>Baseline tumour measurements were performed within 4 weeks prior to treatment start (RECIST). The same methods of assessment (CT and/or MRI) were used for each measurable lesion at baseline and during follow-up.
Complete Response (CR) is disappearance of all clinical and radiological evidence of tumour (both target and non-target lesions).
Partial Response (PR) is at least a 30% decrease in the sum of LD of target lesions, taking as reference the baseline sum of tumour longest diameters (LD).
Stable Disease (SD) is steady state of disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Progressive Disease (PD) is at least a 20% increase in the sum of LD of measured lesions taking as references the smallest sum LD recorded since the treatment started. Appearance of new lesions constitutes PD. In exceptional circumstances, unequivocal progression of non-target lesions was considered evidence of PD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Types and Numbers of Adverse Events - General Overview</measure>
    <time_frame>continuous up to 1 year</time_frame>
    <description>Adverse events graded as per NCI CTCAE (US National Cancer Institute Common Terminology Criteria for Adverse Events) version 3.0. All Serious Adverse Events occurrences are reported and counts are summarized here; all Adverse Events (all grades) related and not related to study treatment are reported and summarized here; all severe laboratory events (hematology and biochemistry Gr 3 and higher) are reported and summarized here; all severe postoperative complications (Gr 3 and higher) occurred within the first month post surgery are reported and summarized here. See section Adverse events for details.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence Rates and Disease Free Survival</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Counts and proportions of patients experiencing recurrence of disease (local and distant).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death Rates and Overall Survival</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Counts and proportions of patients deceased (post-study).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Locally Advanced Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>AXE (ARM 1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxaliplatin, Bevacizumab and Capecitabine concurrently with radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AX (ARM 2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bevacizumab and Capecitabine concurrently with radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Administered on days 15,22,29,36 en 43; 50 mg/m2</description>
    <arm_group_label>AXE (ARM 1)</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Administered on days 1,15,29 and 43 ; 5mg/kg</description>
    <arm_group_label>AX (ARM 2)</arm_group_label>
    <arm_group_label>AXE (ARM 1)</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy</description>
    <arm_group_label>AX (ARM 2)</arm_group_label>
    <arm_group_label>AXE (ARM 1)</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>Total dose 45Gy</description>
    <arm_group_label>AX (ARM 2)</arm_group_label>
    <arm_group_label>AXE (ARM 1)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adenocarcinoma of rectum measurable (RECIST), locally advanced (defined by MRI -
             Tumour beyond mesorectal fascia (T4) or Tumour ≤ 2 mm from mesorectal fascia or T3
             tumour &lt; 5 cm from anal verge

          -  Patient is at least 18 years of age

          -  Good organ function

        Exclusion Criteria:

          -  Evidence of distant metastases

          -  Contraindication for bevacizumab

          -  Pregnant or breastfeeding women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Van Cutsem, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Onze Lieve Vrouwziekenhuis</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerp</city>
        <zip>ZNA Middelheim</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ St- Lucas</name>
      <address>
        <city>Brugge</city>
        <zip>8310</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasme Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. Sart-Tilman</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Hartziekenhuis</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 23, 2009</study_first_submitted>
  <study_first_submitted_qc>January 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2009</study_first_posted>
  <results_first_submitted>December 21, 2017</results_first_submitted>
  <results_first_submitted_qc>July 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 10, 2019</results_first_posted>
  <last_update_submitted>July 9, 2019</last_update_submitted>
  <last_update_submitted_qc>July 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bevacizumab</keyword>
  <keyword>capecitabine</keyword>
  <keyword>radiation therapy</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>multimodality treatments</keyword>
  <keyword>TME (total mesorectal excision)</keyword>
  <keyword>Axe Beam</keyword>
  <keyword>rectal cancer</keyword>
  <keyword>neoadjuvant</keyword>
  <keyword>pathological complete response</keyword>
  <keyword>postoperative complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eighty-four patients were included. First patient enrolled: 22-Jun-2009. Last patient enrolled: 29-Sep-2013. Participating sites: UZ Leuven, Erasme Hospital Bruxelles, Cliniques Universitaires St-Luc Bruxelles, AZ St. Lucas Brugge, AZ Groeninge Kortrijk, CHU Sart-Tilman Liege, OLVZ Aalst, H. Hart Ziekenhuis Roeselare, Cl. Saint Elisabeth Namur</recruitment_details>
      <pre_assignment_details>Target population was represented by patients with locally advanced rectal cancer (tumour beyond mesorectal fascia (T4) or tumour ≤ 2 mm from mesorectal fascia or T3 tumour &lt; 5 cm from anal verge by MRI), histologically confirmed. Pts were screened as per incl and excl criteria per protocol. Screening failures were not recorded in the eCRF.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AXE (ARM 1)</title>
          <description>Oxaliplatin, Bevacizumab and Capecitabine concurrently with radiotherapy.
Oxaliplatin: Administered on days 15,22,29,36 en 43; 50 mg/m2
Bevacizumab: Administered on days 1,15,29 and 43 ; 5mg/kg
Capecitabine: 825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
Radiotherapy: Total dose 45Gy</description>
        </group>
        <group group_id="P2">
          <title>AX (ARM 2)</title>
          <description>Bevacizumab and Capecitabine concurrently with radiotherapy
Bevacizumab: Administered on days 1,15,29 and 43 ; 5mg/kg
Capecitabine: 825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
Radiotherapy: Total dose 45Gy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Pre-treatment (Baseline)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Study Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Complete response, no surgery</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Post-surgery (&lt;30 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No central review materials</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42">Patient in Arm 1 with clinical complete response and no surgery is in follow up (joined this period)</participants>
                <participants group_id="P2" count="41">Patients with no central review material and with adverse event are in followup (joined this period)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AXE (ARM 1)</title>
          <description>Oxaliplatin, Bevacizumab and Capecitabine concurrently with radiotherapy.
Oxaliplatin: Administered on days 15,22,29,36 en 43; 50 mg/m2
Bevacizumab: Administered on days 1,15,29 and 43 ; 5mg/kg
Capecitabine: 825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
Radiotherapy: Total dose 45Gy</description>
        </group>
        <group group_id="B2">
          <title>AX (ARM 2)</title>
          <description>Bevacizumab and Capecitabine concurrently with radiotherapy
Bevacizumab: Administered on days 1,15,29 and 43 ; 5mg/kg
Capecitabine: 825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
Radiotherapy: Total dose 45Gy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="84"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="26" upper_limit="77"/>
                    <measurement group_id="B2" value="59" lower_limit="35" upper_limit="78"/>
                    <measurement group_id="B3" value="60" lower_limit="26" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG PS (Performance Status)</title>
          <description>ECOG PS = 0 Fully active, able to carry on all pre-disease performance without restriction; ECOG PS = 1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>ECOG PS=0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG PS=1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Distance from tumour to anal verge</title>
          <description>Distance from tumour to anal verge measured during colonoscopy (in cm).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;5cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=5cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Distance to CRM</title>
          <description>Distance to CRM measured by MRI</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>0mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;2mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=2mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumour stage</title>
          <description>Tumour staging was done using clinical, radiological and pathological assessments on rectal biopsies. Tumors (T) were graded using the colon and rectum cancer staging (TNM, American Joint Committee on Cancer 7th edition) where T2 tumors are less severe then T3 tumors and T4 tumors respectively.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>T2 (Tumor invades muscularis propria)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3 (tumor invades into pericolorectal tissues)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4 (tumor invades through peritoneum/other organs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nodal stage</title>
          <description>Nodal staging was done using clinical, radiological and pathological assessments where applicable. Lymph node involvement (N) was graded using the colon and rectum cancer staging (TNM, American Joint Committee on Cancer 7th edition) where N0 is no regional lymph node involved and N1 is less severe then N2 involvement.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>N0 (no regional lymph node metastase)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N1 (metastasis in 1-3 regional lymp nodes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N2 (metastasis in 4 or more regional lymph nodes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nx (regional nodes cannot be assessed)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pathologic Response at Surgery. Overview of Complete Pathologic Responses, Good and Little Tumour Regression Rates at Surgery.</title>
        <description>Dworak tumour regression grades (TRG) were used to assess pathologic response: TRG0=no regression. TRG1=dominant tumor mass with obvious fibrosis and/or vasculopathy; TRG2=dominant fibrotic changes with few tumour cells or groups; TRG3=very few (difficult to find microscopically) tumour cells in fibrotic tissue with or without mucus substance. TRG4=no intact viable tumour cells, only fibrotic mass or presence of mucin lakes without associated malignant cells (total tumour regression). Pathologic assessments of tumour response post chemoradiotherapy as provided by investigators (read by local pathologists on operative specimens) were reviewed centrally for all pts for whom surgical materials were available (centrally reviewed set). The diagnosis of independent central reviewers primed. Pathologic complete response rates (TRG4) are reported (%). Good (TRG3 and TRG4 together) and little (TRG 0,1 and 2) tumour regression rates are summarized. For these 2 last rows, % add to 100.</description>
        <time_frame>4 months</time_frame>
        <population>Patients who had undertaken surgery and had pathology materials available for central review (centrally reviewed subset)</population>
        <group_list>
          <group group_id="O1">
            <title>AXE (ARM 1)</title>
            <description>Oxaliplatin, Bevacizumab and Capecitabine concurrently with radiotherapy.
Oxaliplatin: Administered on days 15,22,29,36 en 43; 50 mg/m2
Bevacizumab: Administered on days 1,15,29 and 43 ; 5mg/kg
Capecitabine: 825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
Radiotherapy: Total dose 45Gy</description>
          </group>
          <group group_id="O2">
            <title>AX (ARM 2)</title>
            <description>Bevacizumab and Capecitabine concurrently with radiotherapy
Bevacizumab: Administered on days 1,15,29 and 43 ; 5mg/kg
Capecitabine: 825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
Radiotherapy: Total dose 45Gy</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Response at Surgery. Overview of Complete Pathologic Responses, Good and Little Tumour Regression Rates at Surgery.</title>
          <description>Dworak tumour regression grades (TRG) were used to assess pathologic response: TRG0=no regression. TRG1=dominant tumor mass with obvious fibrosis and/or vasculopathy; TRG2=dominant fibrotic changes with few tumour cells or groups; TRG3=very few (difficult to find microscopically) tumour cells in fibrotic tissue with or without mucus substance. TRG4=no intact viable tumour cells, only fibrotic mass or presence of mucin lakes without associated malignant cells (total tumour regression). Pathologic assessments of tumour response post chemoradiotherapy as provided by investigators (read by local pathologists on operative specimens) were reviewed centrally for all pts for whom surgical materials were available (centrally reviewed set). The diagnosis of independent central reviewers primed. Pathologic complete response rates (TRG4) are reported (%). Good (TRG3 and TRG4 together) and little (TRG 0,1 and 2) tumour regression rates are summarized. For these 2 last rows, % add to 100.</description>
          <population>Patients who had undertaken surgery and had pathology materials available for central review (centrally reviewed subset)</population>
          <units>percentage of cases</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pathological complete response (Dworak TRG=4) %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="19" upper_limit="49"/>
                    <measurement group_id="O2" value="11" lower_limit="0" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good tumour regression (Dworak TRG=3-4) %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="26" upper_limit="57"/>
                    <measurement group_id="O2" value="24" lower_limit="10" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Little tumour regression (Dworak TRG=0-1-2) %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="43" upper_limit="74"/>
                    <measurement group_id="O2" value="76" lower_limit="62" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Histopathologic R0 and Negative CRM Resection</title>
        <description>Histopathologic R0 resection rate was defined as margins histologically negative for tumour involvement after resection. The circumferential resection margin (CRM) is considered to be involved if microscopic tumour is present &lt;1mm from or at the inked circumferential or radial resection margin. Data on quality of mesorectal excision were expected but not collected consistently.</description>
        <time_frame>4 months</time_frame>
        <population>Patient in Arm 2 that discontinued chemoradiotherapy due to major toxicity and had surgery off protocol is counted here as well</population>
        <group_list>
          <group group_id="O1">
            <title>AXE (ARM 1)</title>
            <description>Oxaliplatin, Bevacizumab and Capecitabine concurrently with radiotherapy.
Oxaliplatin: Administered on days 15,22,29,36 en 43; 50 mg/m2
Bevacizumab: Administered on days 1,15,29 and 43 ; 5mg/kg
Capecitabine: 825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
Radiotherapy: Total dose 45Gy</description>
          </group>
          <group group_id="O2">
            <title>AX (ARM 2)</title>
            <description>Bevacizumab and Capecitabine concurrently with radiotherapy
Bevacizumab: Administered on days 1,15,29 and 43 ; 5mg/kg
Capecitabine: 825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
Radiotherapy: Total dose 45Gy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Histopathologic R0 and Negative CRM Resection</title>
          <description>Histopathologic R0 resection rate was defined as margins histologically negative for tumour involvement after resection. The circumferential resection margin (CRM) is considered to be involved if microscopic tumour is present &lt;1mm from or at the inked circumferential or radial resection margin. Data on quality of mesorectal excision were expected but not collected consistently.</description>
          <population>Patient in Arm 2 that discontinued chemoradiotherapy due to major toxicity and had surgery off protocol is counted here as well</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative resection margins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive resection margins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Pathologic Complete Response at Surgery. Number of Participants With Good or Little Pathological Tumour Regression at Surgery.</title>
        <description>Dworak tumour regression grades (TRG) were used to assess pathologic response: TRG0=no regression. TRG1=dominant tumor mass with obvious fibrosis and/or vasculopathy; TRG2=dominant fibrotic changes with few tumour cells or groups; TRG3=very few (difficult to find microscopically) tumour cells in fibrotic tissue with or without mucus substance. TRG4=no intact viable tumour cells, only fibrotic mass or presence of mucin lakes without associated malignant cells (total tumour regression). Pathologic assessments of tumour response post chemoradiotherapy as provided by investigators (read by local pathologists on operative specimens) were reviewed centrally for all pts for whom surgical materials were available (centrally reviewed set). The diagnosis of independent central reviewers primed. Pathologic complete response rates (TRG4) are reported (%). Good (TRG3 and TRG4 together) and little (TRG 0,1 and 2) tumour regression rates are summarized. For these 2 last rows, % add to 100.</description>
        <time_frame>4 months</time_frame>
        <population>Centrally reviewed subset</population>
        <group_list>
          <group group_id="O1">
            <title>AXE (ARM 1)</title>
            <description>Oxaliplatin, Bevacizumab and Capecitabine concurrently with radiotherapy.
Oxaliplatin: Administered on days 15,22,29,36 en 43; 50 mg/m2
Bevacizumab: Administered on days 1,15,29 and 43 ; 5mg/kg
Capecitabine: 825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
Radiotherapy: Total dose 45Gy</description>
          </group>
          <group group_id="O2">
            <title>AX (ARM 2)</title>
            <description>Bevacizumab and Capecitabine concurrently with radiotherapy
Bevacizumab: Administered on days 1,15,29 and 43 ; 5mg/kg
Capecitabine: 825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
Radiotherapy: Total dose 45Gy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pathologic Complete Response at Surgery. Number of Participants With Good or Little Pathological Tumour Regression at Surgery.</title>
          <description>Dworak tumour regression grades (TRG) were used to assess pathologic response: TRG0=no regression. TRG1=dominant tumor mass with obvious fibrosis and/or vasculopathy; TRG2=dominant fibrotic changes with few tumour cells or groups; TRG3=very few (difficult to find microscopically) tumour cells in fibrotic tissue with or without mucus substance. TRG4=no intact viable tumour cells, only fibrotic mass or presence of mucin lakes without associated malignant cells (total tumour regression). Pathologic assessments of tumour response post chemoradiotherapy as provided by investigators (read by local pathologists on operative specimens) were reviewed centrally for all pts for whom surgical materials were available (centrally reviewed set). The diagnosis of independent central reviewers primed. Pathologic complete response rates (TRG4) are reported (%). Good (TRG3 and TRG4 together) and little (TRG 0,1 and 2) tumour regression rates are summarized. For these 2 last rows, % add to 100.</description>
          <population>Centrally reviewed subset</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response, no tumour left Dworak TRG=4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good tumour regression TRG=3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No or little tumour regression Dworak TRG=0-1-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response Rate</title>
        <description>Baseline tumour measurements were performed within 4 weeks prior to treatment start (RECIST). The same methods of assessment (CT and/or MRI) were used for each measurable lesion at baseline and during follow-up.
Complete Response (CR) is disappearance of all clinical and radiological evidence of tumour (both target and non-target lesions).
Partial Response (PR) is at least a 30% decrease in the sum of LD of target lesions, taking as reference the baseline sum of tumour longest diameters (LD).
Stable Disease (SD) is steady state of disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Progressive Disease (PD) is at least a 20% increase in the sum of LD of measured lesions taking as references the smallest sum LD recorded since the treatment started. Appearance of new lesions constitutes PD. In exceptional circumstances, unequivocal progression of non-target lesions was considered evidence of PD.</description>
        <time_frame>3 months</time_frame>
        <population>Intent to treat, all registered patients</population>
        <group_list>
          <group group_id="O1">
            <title>AXE (ARM 1)</title>
            <description>Oxaliplatin, Bevacizumab and Capecitabine concurrently with radiotherapy.
Oxaliplatin: Administered on days 15,22,29,36 en 43; 50 mg/m2
Bevacizumab: Administered on days 1,15,29 and 43 ; 5mg/kg
Capecitabine: 825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
Radiotherapy: Total dose 45Gy</description>
          </group>
          <group group_id="O2">
            <title>AX (ARM 2)</title>
            <description>Bevacizumab and Capecitabine concurrently with radiotherapy
Bevacizumab: Administered on days 1,15,29 and 43 ; 5mg/kg
Capecitabine: 825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
Radiotherapy: Total dose 45Gy</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response Rate</title>
          <description>Baseline tumour measurements were performed within 4 weeks prior to treatment start (RECIST). The same methods of assessment (CT and/or MRI) were used for each measurable lesion at baseline and during follow-up.
Complete Response (CR) is disappearance of all clinical and radiological evidence of tumour (both target and non-target lesions).
Partial Response (PR) is at least a 30% decrease in the sum of LD of target lesions, taking as reference the baseline sum of tumour longest diameters (LD).
Stable Disease (SD) is steady state of disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Progressive Disease (PD) is at least a 20% increase in the sum of LD of measured lesions taking as references the smallest sum LD recorded since the treatment started. Appearance of new lesions constitutes PD. In exceptional circumstances, unequivocal progression of non-target lesions was considered evidence of PD.</description>
          <population>Intent to treat, all registered patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Types and Numbers of Adverse Events - General Overview</title>
        <description>Adverse events graded as per NCI CTCAE (US National Cancer Institute Common Terminology Criteria for Adverse Events) version 3.0. All Serious Adverse Events occurrences are reported and counts are summarized here; all Adverse Events (all grades) related and not related to study treatment are reported and summarized here; all severe laboratory events (hematology and biochemistry Gr 3 and higher) are reported and summarized here; all severe postoperative complications (Gr 3 and higher) occurred within the first month post surgery are reported and summarized here. See section Adverse events for details.</description>
        <time_frame>continuous up to 1 year</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>AXE (ARM 1)</title>
            <description>Oxaliplatin, Bevacizumab and Capecitabine concurrently with radiotherapy.
Oxaliplatin: Administered on days 15,22,29,36 en 43; 50 mg/m2
Bevacizumab: Administered on days 1,15,29 and 43 ; 5mg/kg
Capecitabine: 825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
Radiotherapy: Total dose 45Gy</description>
          </group>
          <group group_id="O2">
            <title>AX (ARM 2)</title>
            <description>Bevacizumab and Capecitabine concurrently with radiotherapy
Bevacizumab: Administered on days 1,15,29 and 43 ; 5mg/kg
Capecitabine: 825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
Radiotherapy: Total dose 45Gy</description>
          </group>
        </group_list>
        <measure>
          <title>Types and Numbers of Adverse Events - General Overview</title>
          <description>Adverse events graded as per NCI CTCAE (US National Cancer Institute Common Terminology Criteria for Adverse Events) version 3.0. All Serious Adverse Events occurrences are reported and counts are summarized here; all Adverse Events (all grades) related and not related to study treatment are reported and summarized here; all severe laboratory events (hematology and biochemistry Gr 3 and higher) are reported and summarized here; all severe postoperative complications (Gr 3 and higher) occurred within the first month post surgery are reported and summarized here. See section Adverse events for details.</description>
          <population>Intent to treat</population>
          <units>counts of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="564"/>
                    <measurement group_id="O2" value="426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe lab events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post operative complications at 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrence Rates and Disease Free Survival</title>
        <description>Counts and proportions of patients experiencing recurrence of disease (local and distant).</description>
        <time_frame>up to 5 years</time_frame>
        <population>Intent to treat (one patient lost to follow-up)</population>
        <group_list>
          <group group_id="O1">
            <title>AXE (ARM 1)</title>
            <description>Oxaliplatin, Bevacizumab and Capecitabine concurrently with radiotherapy.
Oxaliplatin: Administered on days 15,22,29,36 en 43; 50 mg/m2
Bevacizumab: Administered on days 1,15,29 and 43 ; 5mg/kg
Capecitabine: 825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
Radiotherapy: Total dose 45Gy</description>
          </group>
          <group group_id="O2">
            <title>AX (ARM 2)</title>
            <description>Bevacizumab and Capecitabine concurrently with radiotherapy
Bevacizumab: Administered on days 1,15,29 and 43 ; 5mg/kg
Capecitabine: 825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
Radiotherapy: Total dose 45Gy</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence Rates and Disease Free Survival</title>
          <description>Counts and proportions of patients experiencing recurrence of disease (local and distant).</description>
          <population>Intent to treat (one patient lost to follow-up)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Recurred Dec 2017</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not recurred Dec 2017</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lost to FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death Rates and Overall Survival</title>
        <description>Counts and proportions of patients deceased (post-study).</description>
        <time_frame>up to 5 years</time_frame>
        <population>Intent to treat in follow up (one patient in Arm 1 lost to follow up).</population>
        <group_list>
          <group group_id="O1">
            <title>AXE (ARM 1)</title>
            <description>Oxaliplatin, Bevacizumab and Capecitabine concurrently with radiotherapy.
Oxaliplatin: Administered on days 15,22,29,36 en 43; 50 mg/m2
Bevacizumab: Administered on days 1,15,29 and 43 ; 5mg/kg
Capecitabine: 825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
Radiotherapy: Total dose 45Gy</description>
          </group>
          <group group_id="O2">
            <title>AX (ARM 2)</title>
            <description>Bevacizumab and Capecitabine concurrently with radiotherapy
Bevacizumab: Administered on days 1,15,29 and 43 ; 5mg/kg
Capecitabine: 825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
Radiotherapy: Total dose 45Gy</description>
          </group>
        </group_list>
        <measure>
          <title>Death Rates and Overall Survival</title>
          <description>Counts and proportions of patients deceased (post-study).</description>
          <population>Intent to treat in follow up (one patient in Arm 1 lost to follow up).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deceased (Dec 2017)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alive (Dec 2017)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lost to FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From signature of ICF to 30 days post surgery with follow-up for residual toxicity after this period if applicable</time_frame>
      <desc>All SAE occurences are reported and displayed below. Only Gr 3-4-5 adverse events (serious and non serious) are reported in this report.</desc>
      <group_list>
        <group group_id="E1">
          <title>AXE (ARM 1)</title>
          <description>Oxaliplatin, Bevacizumab and Capecitabine concurrently with radiotherapy.
Oxaliplatin: Administered on days 15,22,29,36 en 43; 50 mg/m2
Bevacizumab: Administered on days 1,15,29 and 43 ; 5mg/kg
Capecitabine: 825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
Radiotherapy: Total dose 45Gy</description>
        </group>
        <group group_id="E2">
          <title>AX (ARM 2)</title>
          <description>Bevacizumab and Capecitabine concurrently with radiotherapy
Bevacizumab: Administered on days 1,15,29 and 43 ; 5mg/kg
Capecitabine: 825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
Radiotherapy: Total dose 45Gy</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI CTC AE V3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <description>Rectal haemorrhage Gr 2 following rectal biopsy. During chemoradiotherapy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Diarrhea Gr 3 - During chemoradiotherapy</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <description>Fistula Gr 3 - Postoperative</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Leak</sub_title>
                <description>Anastomotic leak Gr 3; 2 in arm 1 and 3 in arm 2 - all events also SAE - Postoperative</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Obstruction</sub_title>
                <description>Obstruction GI Gr 2 and Gr 3; both arm 1 Postoperative</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Presacral hematoma</sub_title>
                <description>Presacral hematoma Gr 2 - Postoperative</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <description>Fever Gr 1 - During chemoradiotherapy</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Febrile neutropenia Gr 3 - During chemoradiotherapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <description>Catheter related infection Gr 4 - During chemoradiotherapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>Urinary tract infection Gr 2 (1 in each arm) and 1 Urinary tract infection Gr 3 in arm 1 - During chemoradiotherapy</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <description>Catheter site infection Gr 3 with positive hemocultures - Postoperative</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <description>5 peri-anal wound infections Gr 3 (4 in arm 1; 1 in arm 2) ; 1 wound with evisceration Gr 4 in arm 1 ; 1 Gr 5 wound infection in a patient with tumor break during surgery in arm 2</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy motor</sub_title>
                <description>Neuropathy, motor (cranial, palate, pharynx) Gr 3 (swallowing problems) - During chemoradiotherapy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <description>Seizure Gr 2 in a patient with epileptic background - During chemoradiotherapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <description>Depression Gr 3 - During chemoradiotherapy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Lung embolism</sub_title>
                <description>Lung embolism Gr 5 - Postoperative</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>NCI CTC AE V3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <description>Platelet count decreased Gr 3 - during chemoradiotherapy</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <description>Hemorrhage with surgery Gr 3</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dissiminated Intravascular Coagulation</sub_title>
                <description>Disseminated Intravascular Coagulation Gr 3 - during chemoradiotherapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hematoma postoperative</sub_title>
                <description>Hematoma Gr 3 in 1 pt in arm 2 (also SAE) - postoperative</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <description>Hematoma Gr 3 (also an SAE) - FU post EOT visit</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension b</sub_title>
                <description>Hypertension Gr 3 - baseline</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Hypertension Gr 3 in 2 pts in arm 2 - during chemoradiotherapy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary arrest</sub_title>
                <description>Cardiopulmonary arrest Gr 5 - FU post EOT visit</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <description>Pt with baseline Meniere's disease Gr 3 (since 1999) - Baseline</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>Anorexia Gr 3 - during chemoradiotherapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Diarrhea Gr 3 in 4 pts in arm 1 (three episodes were an SAE) - during chemoradiotherapy</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Anal pain</sub_title>
                <description>Pain gastro-intestinal - anal pain Gr 3</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Leak Gi</sub_title>
                <description>Leak GI Gr 3 - postoperative</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Obstruction Gi</sub_title>
                <description>Obstruction GI Gr 3 in 2 pts in arm 1 (for 1 also an SAE) and in 1 pt in arm 2 (also an SAE) - postoperative</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pain GI</sub_title>
                <description>Stomach pain Gr 3 and pain due to leak Gr 3 - postoperative</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Discharge from the anus</sub_title>
                <description>Purulent discharge from the anus Gr - - postoperative</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <description>Ascites Gr 5 - FU post EOT visit</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <description>Dysphagia Gr 3 - FU post EOT visit</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Fatigue Gr 3 (2 pts in arm 1 and 1 pt in arm 2 - also an SAE for this pt) - during chemoradiotherapy</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <description>Sweating Gr 3 - Postoperative</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Febrile neutropenia Gr 3 (also an SAE) - during chemoradiotherapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <description>Catheter site infection Gr 3 (also an SAE) - during chemoradiotherapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>Sepsis Gr 3 and septic shock Gr 4 - during chemoradiotherapy</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <description>5 peri-anal wound infections Gr 3 ; 1 wound infection with evisceration Gr 4 ; 1 Gr 5 wound infection in a patient with tumor break during surgery</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <description>Peritonitis Gr 5 (tumor break during surgery) - part of SAE</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Infection due to leak of anastomosis</sub_title>
                <description>Infection due to leak of anastomosis Gr 3 (part of an SAE) - follow-up</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <description>Hypocalcemia Gr 3 - during chemoradiotherapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <description>Hyponatremia Gr 3 - during chemoradiotherapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain musculoskeletal</sub_title>
                <description>Pain musculoskeletal Gr 3 - Postoperative</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pain muskuloskeletal Gr 3</sub_title>
                <description>Pain muskuloskeletal Gr 3 - postoperative</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <description>Hypokalemia Gr 3 - during chemoradiotherapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy sensory</sub_title>
                <description>Neuropathy sensory Gr 3 - during chemoradiotherapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Syncope Gr 3 - during chemoradiotherapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Neuropathy - cranial</sub_title>
                <description>Neuropathy -cranial Gr 3 (also an SAE) - FU post EOT visit</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <description>Depression Gr 3 - also an SAE - during chemoradiotherapy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Leak GU</sub_title>
                <description>Leak GU Gr 5 - postoperative</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pain pumonary/respiratory</sub_title>
                <description>Sore throat Gr 3 and laryngeal pain Gr 3 in one patient in arm 2 - during chemoradiotherapy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <description>Dermatitis associated with radiotherapy Gr 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Rash Gr 3 - during chemoradiotherapy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep venous thrombosis</sub_title>
                <description>DVT Gr 3 - Postoperative</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <description>Embolism Gr 4 and embolism Gr 5 - both in arm 2</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor is an academic institution and not the drug market authorization holder. Participating PIs were selected from other academic institutions. Participating PIs cannot publish full or partial study results before final publication by Sponsor, but they will be nominated as co-authors based on patient accrual at each participating site. Own results can be published afterwards by participant PIs, with the agreement of the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was not powered to allow for formal statistical comparisons between arms</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Prof. Dr. Eric Van Cutsem</name_or_title>
      <organization>UZ Leuven</organization>
      <phone>+32 16 34 42 18</phone>
      <email>Eric.VanCutsem@uzleuven.be</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

